Skip to content
Olema Pharmaceuticals, Inc. (OLMA) Stock Price, Key Stats & Insider Trading
Home / Companies / OLMA OLM
Olema Pharmaceuticals, Inc. (OLMA) XNAS PHARMACEUTICAL PREPARATIONS Net insider selling (90d)
Latest OLMA Insider Trades
About Olema Pharmaceuticals, Inc. (OLMA) Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Headquarters SAN FRANCISCO, CA
Employees 150
Listed 2020
Exchange XNAS https://www.olema.com SEC filings for OLMA on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 2 25,000 $291K Grant or award 11 324,500
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
OLMA Insider Transactions (Form 4) 58 38 Form 4 filings on record, the earliest from Nov 18, 2024, newest first. Filing history page 1 of 2.
Date Insider Transaction Security Shares Price Value Jul 23, 2026 CH Cyrus Harmon - Director Open-market sale Common Stock 12,500
Recent OLMA Form 8-K Filings 5
Recent OLMA Form 144 Notices of Proposed Sale 2 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Jul 24, 2026 - - - - View on EDGAR Jul 23, 2026 - - -
OLMA Insider Trading - FAQ
What is the latest insider trade for OLMA? Olema Pharmaceuticals, Inc. (OLMA) had 12 insider filings in the last 90 days, with the most recent on 2026-07-27. The full record for OLMA runs to 38 Form 4 filings, the earliest from 2024-11-18. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying OLMA stock? No insider purchases of OLMA were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling OLMA stock? 2 insider sales of OLMA were filed in the last 90 days, totaling $291K.
Where can I see OLMA SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks OLMA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow OLMA insider buys? Create a free InsiderAlpha account and press Watch on this page to add OLMA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track OLMA insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free SM
Market cap $898.60M
P/E ratio -
Dividend yield -
Average volume 1.38M
52 week high $36.26
52 week low $5.36
Today's high $10.77
Today's low $10.19
Open $10.69
Volume 740.8K
Previous close $10.79
Shares outstanding 87.50M Market cap
$898.60M
150 employees
OLMA Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 2 sales totaling $291K.
Most-Active OLMA Insiders - Last 90 Days 10 Jul 24, 2026 CH Cyrus Harmon - Director Open-market sale Common Stock 12,500 $11.71 $146K
Jun 18, 2026 BVF PARTNERS L P - Director Grant or award Stock Option (Right to buy) 29,500 $0.00 -
Jun 18, 2026 CH Cyrus Harmon Grant or award Stock Option (Right to Buy) 29,500 $0.00 -
Jun 18, 2026 JG J. Scott Garland Grant or award Stock Option (right to buy) 29,500 $0.00 -
Jun 18, 2026 IC Ian T. Clark Grant or award Stock Option (right to buy) 29,500 $0.00 -
Jun 18, 2026 YL Yi Larson Grant or award Stock Option (right to buy) 29,500 $0.00 -
Jun 18, 2026 SH Sandra Horning Grant or award Stock Option (right to buy) 29,500 $0.00 -
Jun 18, 2026 PR Prakash Raman Grant or award Stock Option (right to buy) 29,500 $0.00 -
Jun 18, 2026 AR Andrew Rappaport Grant or award Stock Option (right to buy) 29,500 $0.00 -
Apr 28, 2026 PR Prakash Raman Grant or award Stock Option (Right to Buy) 2,911 $0.00 -
Apr 28, 2026 PR Prakash Raman Grant or award Stock Option (Right to Buy) 24,150 $0.00 -
Mar 4, 2026 SM Shawnte Mitchell - Officer Open-market sale Common Stock 24,767 $24.25 $601K
Mar 3, 2026 SM Shawnte Mitchell - Officer Option exercise Stock Option (Right to Buy) 15,000 $0.00 -
Mar 4, 2026 SM Shawnte Mitchell - Officer Option exercise Stock Option (Right to Buy) 25,000 $0.00 -
Mar 3, 2026 SM Shawnte Mitchell - Officer Option exercise Common Stock 15,000 $4.37 $66K
Mar 4, 2026 SM Shawnte Mitchell - Officer Option exercise Common Stock 25,000 $4.37 $109K
Mar 3, 2026 SM Shawnte Mitchell - Officer Open-market sale Common Stock 15,000 $23.01 $345K
Feb 2, 2026 SA Sasha Lu Austin - Officer Grant or award Common Stock 11,700 $0.00 -
Feb 2, 2026 SA Sasha Lu Austin - Officer Grant or award Stock Option (Right to Buy) 29,250 $0.00 -
Feb 2, 2026 NZ Naseem Zojwalla - Officer Grant or award Stock Option (Right to Buy) 250,000 $0.00 -
Feb 2, 2026 NZ Naseem Zojwalla - Officer Grant or award Performance Stock Options (Right to Buy) 106,250 $0.00 -
Feb 2, 2026 DM David C. Myles - Officer Grant or award Stock Option (Right to Buy) 250,000 $0.00 -
Feb 2, 2026 DM David C. Myles - Officer Grant or award Performance Stock Options (Right to Buy) 106,250 $0.00 -
Feb 2, 2026 SM Shawnte Mitchell - Officer Grant or award Stock Option (Right to Buy) 220,000 $0.00 -
Feb 2, 2026 SM Shawnte Mitchell - Officer Grant or award Performance Stock Options (Right to Buy) 56,250 $0.00 -
Feb 2, 2026 SB Sean Bohen - Officer Grant or award Stock Option (Right to Buy) 850,000 $0.00 -
Feb 2, 2026 SB Sean Bohen - Officer Grant or award Performance Stock Options (Right to Buy) 275,000 $0.00 -
Jan 20, 2026 CH Cyrus Harmon Open-market sale Common Stock 10,000 $26.88 $269K
Jan 14, 2026 CH Cyrus Harmon Open-market sale Common Stock 3,489 $29.12 $102K
Jan 13, 2026 DM David C. Myles - Officer Open-market sale Common Stock 200 $28.49 $6K
Jan 14, 2026 DM David C. Myles - Officer Option exercise Common Stock 50,000 $4.87 $244K
Jan 12, 2026 DM David C. Myles - Officer Open-market sale Common Stock 10,000 $28.34 $283K
Jan 13, 2026 DM David C. Myles - Officer Option exercise Common Stock 50,000 $4.87 $244K
Jan 13, 2026 DM David C. Myles - Officer Open-market sale Common Stock 49,800 $27.60 $1.37M
Jan 14, 2026 DM David C. Myles - Officer Open-market sale Common Stock 14,997 $28.60 $429K
Jan 14, 2026 DM David C. Myles - Officer Open-market sale Common Stock 35,003 $28.99 $1.01M
Jan 13, 2026 DM David C. Myles - Officer Option exercise Stock Option (Right to Buy) 50,000 $0.00 -
Jan 14, 2026 DM David C. Myles - Officer Option exercise Stock Option (Right to Buy) 50,000 $0.00 -
Nov 21, 2025 AR Andrew Rappaport Option exercise Stock Option (right to buy) 35,868 $0.00 -
Sep 16, 2025 CH Cyrus Harmon Open-market sale Common Stock 10,000 $8.04 $80K
Sep 18, 2025 CH Cyrus Harmon Open-market sale Common Stock 10,000 $8.33 $83K
Sep 16, 2025 CH Cyrus Harmon Open-market sale Common Stock 1,914 $8.08 $15K
Sep 18, 2025 CH Cyrus Harmon Open-market sale Common Stock 3,086 $8.32 $26K
Jun 11, 2025 BVF PARTNERS L P - Director Grant or award Stock Option (Right to buy) 24,150 $0.00 -
Jun 11, 2025 AR Andrew Rappaport Grant or award Stock Option (right to buy) 24,150 $0.00 -
Dec 17, 2024 GG G. Walmsley Graham - Director Open-market purchase Common Stock 700,761 $6.75 $4.73M
$OPK
OPKO HEALTH, INC.
$IONS
IONIS PHARMACEUTICALS INC
